Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Non-cash Items (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Non-cash Items data on record, last reported at $683000.0 in Q3 2025.

  • For Q3 2025, Non-cash Items rose 175.4% year-over-year to $683000.0; the TTM value through Sep 2025 reached $683000.0, up 175.4%, while the annual FY2024 figure was $249000.0, 92.09% down from the prior year.
  • Non-cash Items reached $683000.0 in Q3 2025 per BTAI's latest filing, up from $259000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $22.8 million in Q1 2022 and bottomed at $248000.0 in Q3 2024.
  • Average Non-cash Items over 4 years is $7.1 million, with a median of $3.2 million recorded in 2023.
  • The widest YoY moves for Non-cash Items: up 175.4% in 2025, down 96.12% in 2025.
  • A 4-year view of Non-cash Items shows it stood at $15.5 million in 2022, then crashed by 79.66% to $3.1 million in 2023, then plummeted by 92.09% to $249000.0 in 2024, then soared by 174.3% to $683000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $683000.0 in Q3 2025, $259000.0 in Q1 2025, and $249000.0 in Q4 2024.